



**EUROPEAN
CURRICULUM**

VITAE FORMAT

PERSONAL INFORMATION

Name	MARIA VITTORIA DIECI
Address	University of Padova Department of Surgery, Oncology and Gastroenterology Istituto Oncologico Veneto IRCCS Division of Medical Oncology 2 Via Gattamelata 64 35128 Padova
Phone	+39-0498215295
Fax	+39-0498215932
Email	mariavittoria.dieci@unipd.it mariavittoria.dieci@ioveneto.it
Nationality	Italian
Date of birth	December 4, 1982
Orcid	https://orcid.org/0000-0002-3967-9861

**WORK/ACADEMIC
EXPERIENCE**

Dates (from-to)	July 2021 - present
Name of the employer	University of Padova Department of Surgery, Oncology and Gastroenterology
Occupation or position held	ASSOCIATE PROFESSOR IN MEDICAL ONCOLOGY
Dates (from-to)	February 2019 – July 2021
Name of the employer	University of Padova Department of Surgery, Oncology and Gastroenterology
Occupation or position held	ASSISTANT PROFESSOR IN MEDICAL ONCOLOGY
Dates (from-to)	June 2017 – present
Name of the employer	University of Padova Department of Surgery, Oncology and Gastroenterology
Occupation or position held	SECRETARY OF THE SPECIALIZATION SCHOOL IN MEDICAL ONCOLOGY
Dates (from-to)	February 2016 – February 2019
Name of the employer	University of Padova Department of Surgery, Oncology and Gastroenterology
Occupation or position held	RESEARCH FELLOW IN MEDICAL ONCOLOGY (RICERCATORE TEMPO DETERMINATO TIPO A)
Dates (from-to)	February 2016 – present
Name of the employer	Veneto Institute of Oncology IOV-IRCCS, Padova Medical Oncology 2

Occupation or position held	ATTENDING PHYSICIAN
Dates (from-to)	January 2014 – January 2016
Name of the employer	Veneto Institute of Oncology IOV-IRCCS, Padova Medical Oncology 2
Occupation or position held	MEDICAL ONCOLOGIST ON CONTRACT
Dates (from-to)	April 2014 – January 2016
Name of the employer	University of Padova Department of Surgery, Oncology and Gastroenterology
Occupation or position held	RESEARCH CONTRACT
Dates (from-to)	April 2014 – January 2016
Name of the employer	University of Padova Department of Surgery, Oncology and Gastroenterology
Occupation or position held	PROFESSOR ON CONTRACT – didactic activity for the Specialization School in Medical oncology
Dates (from-to)	April 2012 –April 2014
Name of the employer	University of Modena and Reggio Emilia Department of Medical and Surgical Sciences of Mother, Child and Adult
Occupation or position held	RESEARCH CONTRACT
Dates (from-to)	May 2012 – October-2013
Name of the employer	Université Paris Sud Gustave Roussy Institute, Villejuif (France)
Occupation or position held	VISITING RESEARCH FELLOW - DIPLOME UNIVERSITAIRE EUROPEEN DE RECHERCHE TRANSLATIONELLE ET CLINIQUE EN CANCEROLOGIE (STUDENT)

EDUCATION AND TRAINING

Dates (from-to)	2021- ongoing
Title of qualification awarded	“LEADERS GENERATION PROGRAMME 2020-2021” - PARTICIPANT
Name and type of organization	European Society of Medical Oncology (ESMO)
Dates (from-to)	2017
Title of qualification awarded	SCIENTIFIC QUALIFICATION FOR ASSOCIATE PROFESSOR IN MEDICAL ONCOLOGY (validity : April 2017 – April 2026)
Dates (from-to)	November 2012 - November 2013
Title of qualification awarded	DIPLOME UNIVERSITAIRE EUROPEEN DE RECHERCHE TRANSLATIONELLE ET CLINIQUE EN CANCEROLOGIE
Principal subjects/occupational skills covered	Translational research in breast cancer Title of final thesis : “Whole exome sequencing of rare aggressive breast cancer histologies: a help to discover novel pathways for breast cancer progression”
Name and type of organization	Université Paris Sud Institut Gustave Roussy, Villejuif (France)

Dates (from-to)	13-18 march 2010
Title of qualification awarded	9TH ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY
Name and type of organization	ESO-ESMO
Dates (from-to)	2008 - 2012
Title of qualification awarded	SPECIALIZATION IN MEDICAL ONCOLOGY, 110/110 cum Laude
Principal subjects/occupational skills covered	Title of the final thesis: "Discordance in biomarkers expression from primary to relapsed breast cancer: prognostic impact"
Name and type of organization	University of Modena and Reggio Emilia
Dates (from-to)	February 2008
Title of qualification awarded	MEDICAL LICENSE
Dates (from-to)	2001 - 2007
Title of qualification awarded	MEDICAL DOCTOR, 110/110 cum Laude
Principal subjects/occupational skills covered	Title of the final thesis: "Modulation of biomarkers expression after neoadjuvant chemotherapy for operable breast cancer: prognostic and predictive value"
Name and type of organization	Università degli studi di Modena e Reggio Emilia
Dates (from-to)	2001
Title of qualification awarded	HIGH SCHOOL DIPLOMA, 100/100
Name and type of organization	Liceo Scientifico Statale A.F. Formiggini, Sassuolo (Modena)

**RESEARCH GRANTS (PI)
 /AWARDS**

- Research grant from the 5x1000 IOV program (2018)
- Research grant from the Italian Ministry of Health (GR-2016-02361279).
- Research grant from DiSCOG – Unipd (BIRD178549/17)
- Fondazione Chianello Award 2016 – University of Palermo
- January 2015: 1° classified "BACK FROM SAN ANTONIO 2015 AWARD" for the best published paper by a young oncologist in the year 2014: "Prognostic value of tumor infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: A retrospective multicenter study", Annals of Oncology 2014.
- November 2012: Monica Boscolo Research Grant 2012, project title: "Prognostic role of lymphocyte infiltrate in residual invasive disease after neoadjuvant therapy for HER2-positive and triple-negative breast cancer".

SCIENTIFIC AFFILIATIONS

AIOM (Associazione Italiana Oncologia Medica):
-scientific secretary “Breast Cancer AIOM Guidelines” (2018-2020)
-panelist “Breast Cancer AIOM Guidelines” (2021-ongoing)
-member of the AIOM YOUNG working group (2015-2017)
-vice-coordinator of the AIOM YOUNG working group (2017-2019)
- member of the Scientific Committee of the AIOM Young National Congress (2016-2018)

ESMO (European Society of Medical Oncology):
- Scientific committee member ESMO 2021 Congress (Track:metastatic breast cancer)
- “Leaders Generation Programme 2020-2021” participant – ongoing

ASCO (American Society of Clinical Oncology) member

ACC (Alleanza Contro il Cancro), Italian ministry of health
Member of the Immunotherapy Working Group since 2017

Didactic Commission of the department of Surgery, oncology and Gastroenterology of the /University of Padova: member since 2020

MOTHER TONGUE

Italian

OTHER LANGUAGES

English

Reading skills EXCELLENT
Writing skills EXCELLENT
Verbal skills EXCELLENT

June 2001: “Certificate Grade B” First Certificate in English (University of Cambridge Examinations Syndicate of Modena).

French

Reading skills EXCELLENT
Writing skills EXCELLENT
Verbal skills EXCELLENT

ANNEXES

- 1. Reviewer activity**
- 2. Research projects**
- 3. Publications**
- 4. Oral presentations at national and international congresses**

CV ANNEXES:

1. REVIEWER ACTIVITY

The Lancet, Annals of Oncology, European Journal of Cancer, Breast Cancer Research, The Oncologist, BMC Cancer, PLOS ONE, The Breast, Cancer Treatment Reviews, Oncoimmunology, Journal of Clinical Pathology, Frontiers in Oncology, ESMO Open, Breast Cancer Research and Treatment

2. RESEARCH PROJECTS AND COLLABORATIONS:

2.1 RESEARCH PROJECTS

- Principal investigator

- "Profiling the immune contexture of early Luminal B breast tumors: translational analysis of the prospective GIADA clinical trial of neoadjuvant immunotherapy. (5x1000 grant, Istituto Oncologico Veneto, Padova, Italy)
- "Tracking the dynamic evolution of ESR1 and PIK3CA mutations on circulating tumor DNA in metastatic breast cancer patients receiving endocrine maintenance treatment: a translational analysis of the prospective, multicenter, randomized MAIN-A study" (Ricerca Finalizzata Ministeriale 2016 – giovani ricercatori GR-2016-02361279)
- "Biomarkers analysis of ShortHER study" (5x1000, Istituto Oncologico Veneto, Padova, Italy)
- "The intestinal microbiome and breast cancer: an exploratory study on patients undergoing neoadjuvant chemotherapy – MOON" – Sponsor: DiSCOG Università di Padova (BIRD178549/17)
- "Tumor immune microenvironment in recurrent breast cancer». DOR1830512/18 - Ricerca Scientifica DOR - Università di Padova
- "Tumor infiltrating lymphocytes in recurrent breast cancer: prognostic value according to tumor phenotype." DOR1685131/16 e DOR1721185/17 – Ricerca Scientifica DOR – Università di Padova
- "Correlation between tumor infiltrating lymphocytes and 21-gene recurrence score in a multicentric cohort of HR+/HER2- early breast cancer patients enrolled in prospective studies." DOR1915571/19 - Ricerca Scientifica DOR - Università di Padova
- "Tracking the dynamic evolution of PIK3CA and ESR1 mutation on ctDNA in HR+/HER2- metastatic breast cancer patients" DOR2029840/20 - Ricerca Scientifica DOR - Università di Padova
- "Valutazione di marcatori immuno-correlati tumorali e legati all'ospite in pazienti oncologici trattati con terapia standard ed immunoterapia: analisi retrospettiva-prospettica." Ricerca Corrente IOV - L02P03
- Clinical coordinator: "Impatto dell'introduzione del test Oncotype DX nella pratica clinica nella Regione Veneto per pazienti affette da carcinoma mammario precoce con recettori estrogenici positive: personalizzazione del trattamento adiuvante e ottimizzazione delle risorse" (Programma per la ricerca e innovazione HTA PRIHTA, Bando 2013, PI: Pierfranco Conte)

- Collaborator:

- "Treatment optimization of HER2 positive breast cancer" (Ministero della Salute, RF-2009-1472600, 2009-2012)
- "Molecular basis for triple negative breast cancer metastasis: new tools for diagnosis and therapy" (Special Program in Molecular Oncology AIRC 5x1000, PI: G. Del Sal)
- "Challenging the role of chemotherapy in HER2 positive early breast cancer: PI3KCA pathways alteration and response to neoadjuvant pertuzumab-trastuzumab plus letrozole or paclitaxel in Hormone Receptor positive-HER2 positive breast cancer patients" (Ricerca Finalizzata Ministeriale 2013 – giovani ricercatori – GR-2013-02356771 - Responsabile prof. Valentina Guarnieri)

- “PIK3CA pathway activation and tumor infiltrating lymphocytes (TIL) to predict outcome of HER2+ early breast cancer (EBC) patients treated with trastuzumab-based therapy in the prospective randomized phase III Short-Her trial” (Progetti di Ricerca di Ateneo, CPDA130927, anno 2013)
- “PIK3CA mutations/PTEN loss and infiltrating tumor lymphocytes to personalize therapy in HER2+ early breast cancer” (My First AIRC Grant 2014, PI: Valentina Guarneri)
- “Immune microenvironment in melanoma and breast cancer patients treated with electrochemotherapy”. (Università di Padova [BIRD171789](#))
- “Prognostic role of infiltrating tumor lymphocytes in HER2+ early breast cancer patients entered into the prospective randomized ShortHer trial comparing two different durations of trastuzumab administration”. (Università di Padova - ex-60%, 60A07-8098/13)
- “Neoadjuvant therapy for operable breast cancer: a model to personalize cancer therapy” (Università di padova – p ex-60%, 60A07-7808/13)
- “PIK3CA mutations and survival in HER2-positive breast cancer patients treated with neoadjuvant trastuzumab and lapatinib” (Università di Padova - ex-60%, 60A07-9077/14)
- “Prognostic and predictive role of tumor infiltrating lymphocytes in HER2 + breast cancer patients treated with neoadjuvant trastuzumab and pertuzumab” (Università di Padova - ex 60% - 60A07-0144/14)
- “Prognostic and predictive factors in breast cancer patients treated with neoadjuvant therapy” (Università di Padova - ex-60% - 60A07-8815/15)
- “Characterization of immune landscapes of tumors in the post-treatment setting”. BCRF Project (leader: Sherene Loi).
- “Metastasis as a mechanodisease” (Special Program AIRC 5x per mille, ID. 22759 PI: S. Piccolo)

2.2 PHASE II OR III CLINICAL TRIALS:

- Collaborator in investigator-driven trials
 - “ADJUVANT TREATMENT FOR HIGH-RISK TRIPLE NEGATIVE BREAST CANCER PATIENTS WITH THE ANTI-PD-L1 ANTIBODY AVELUMAB: A PHASE III RANDOMIZED TRIAL” EUDRACT: 2016-000189-45. Promotore: Dipartimento di Scienze Chirurgiche, Oncologiche e Gastroenterologiche - Università di Padova
 - “Engaging the immune system to improve the efficacy of neoadjuvant chemo-endocrine therapy for premenopausal luminal b breast cancer patients- The GIADA Trial” EUDRACT: 2016-004665-10. Promotore: Dipartimento di Scienze Chirurgiche, Oncologiche e Gastroenterologiche - Università di Padova
 - “PER-ELISA: PERTuzumab-trastuzumab plus IetrozoLe In endocrine Sensitive breast cancer: a phase II neoAdjuvant study” EUDRACT: 2013-002662-40
 - “MAINTenance Afinitor (MAIN-A): A randomized trial comparing maintenance Aromatase Inhibitors (AIs) + everolimus (Afinitor) vs. AIs in patients with HR+ metastatic breast cancer with disease control after first line chemotherapy” EUDRACT: 2013-004153-24
 - “Chemotherapy plus lapatinib or trastuzumab or both in HER2+ primary breast cancer. A randomized phase IIb study with biomarker evaluation.” 2006-001839-21
 - “Phase II, open label, study of primary chemotherapy with Bevacizumab in association with carboplatin, paclitaxel in early and locally advanced triple negative (ER, PgR and HER2 negative) breast cancer” EUDRACT: 2010-022077-33
- Co-investigator in several phase II or III profit clinical trials.

2.3 PROSPECTIVE OR RETROSPECTIVE OBSERVATIONAL CLINICAL STUDIES AS PRINCIPAL INVESTIGATOR:

- “Prospective multicenter registry to assess the impact of the Oncotype DX® Breast Cancer Assay on Resources Optimization and Treatment Decisions for Women with Estrogen Receptor-Positive, Node-Negative and Node-Positive Breast Carcinoma - ROXANE”. Sponsor: Istituto Oncologico Veneto IRCCS, Padova. Code CE IOV 2016/66

- "UTILIZZO DI SCALP-COOLER DIGNICAP® IN PAZIENTI CON CAR-CINOMA MAMMARIO TRATTATE CON CHEMIOTERAPIA: VALUTAZIONE DEL GRADO DI SODDISFAZIONE, DELLA QUALITÀ DI VITA E DEL BENESSERE PSICOFISICO – STUDIO PROTECT" Sponsor: Istituto Oncologico Veneto IRCCS, Padova. Code CE IOV 2016/29
- "NEO-TIL: studio retrospettivo monocentrico in pazienti con carcinoma mammario HER2 positivo o triplo-negativo sottoposte a chemioterapia NEOadiuvante: valutazione dei livelli di Tumor-infiltrating lymphocytes (TIL)" Sponsor: Istituto Oncologico Veneto IRCCS. CE IOV: Notifica 10 del 2016.
- "Alterazioni del gusto indotte da chemioterapia in pazienti con carcinoma della mammella: studio osservazionale – prospettico. Protocollo TASTE". Sponsor: Istituto Oncologico Veneto. Code CE IOV: 2020/75
- "Prognostic factors in phylloides tumors of breast: a retrospective observational monocentric study". Sponsor: Istituto Oncologico Veneto IRCCS. Code CE IOV: 2020/20.
- "Impatto prognostico del BMI in pazienti con diagnosi di carcinoma della mammella in stadio precoce: studio retrospettivo monocentrico – BACON". Sponsor: Istituto Oncologico Veneto IRCCS. Code CE IOV: 2019/48.
- "PROTECT2: Studio osservazionale sull'efficacia e la sicurezza del sistema di scalp-cooler DigniCap® per la prevenzione dell'alopecia in pazienti con carcinoma mammario trattate con chemioterapia". Sponsor: Istituto Oncologico Veneto IRCCS. Code CE IOV: 2019/23.
- "CEROS: metastasi cerebrali da carcinoma mammario: studio osservazionale retrospettivo" Promotore: Istituto Oncologico Veneto IRCCS – Padova. CE IOV : Notifica 12 del 2016.
- "Evaluation of adjuvant chemotherapy costs for estrogen receptor (ER)-positive HER2-negative breast cancer patients in the Veneto Region in Italy - ECHOES". Sponsor: Istituto Oncologico Veneto IRCCS. CE IOV : Notifica 17 del 2016
- "Trattamento del carcinoma mammario avanzato HR positivo ed HER2 negativo : protocollo osservazionale sull'uso di palbociclib – REAL_PAL" - Sponsor: Istituto Oncologico Veneto IRCCS. Code CE IOV 2018/52
- "Caratterizzazione epigenetica di metastasi cerebrali da carcinoma mammario: uno studio retrospettivo multicentrico - EPICHA" – Sponsor: DiSCOG Università di Padova. Code CE IOV: 2018/50.
- "Studio retrospettivo di caratterizzazione mediante GENE expression profiling del carcinoma mammario HER2 positivo – GEN_HER" – Sponsor: Istituto Oncologico Veneto IRCCS. Code CE IOV: 2018/35
- "NEO-ORG: ORGANOIDI TUMORALI DERIVATI DA PAZIENTI CON CARCINOMA MAMMARIO TRIPLO NEGATIVO O HER2-POSITIVO CANDIDATE A TERAPIA NEOADIUVANTE" Sponsor: Istituto Oncologico veneto IRCCS, Padova (in collaboration with the Department of Molecular Medicine - Prof. Piccolo - Università di Padova). Code CE IOV : 2015/17

2.4 INTERNATIONAL COLLABORATIONS:

- Active member of the International TIL Working Group (Hudecek J, et al. NPJ Breast Cancer 2020 ; Kos Z, et al. NPJ Breast cancer 2020 ; Amgad M et al., NPJ Breast Cancer 2020 ; Gonzalez-Ericsson PI et al., J Pathol 2020 ; Park JH et al., Ann oncol 2019 ; Loi S et al., J Clin Oncol 2019 ; Luen SJ et al., Ann Oncol 2019 ; Dieci MV et al, Semin Cancer Biol 2018 ; Hendry S et al., Adv Anat Pathol 2017 ; Hendry S et al., Adv Anat pathol 2017)
- Member of the Immuno-Task Force of the Breast International Group (BIG)/North American Breast Cancer Group (NABCG), year 2017.
- Collaboration with the Translational Genomics and Targeted Therapeutics in Solid Tumors Laboratory, August Pi i Sunyer Biomedical Research Institute (IDIBAPS) and University of Barcelona (Aleix Prat) for the evaluation and validation of prognostic and predictive factors in HER2+ breast cancer (Dieci MV et al., Ann Oncol 2016 ; Prat A et al., J Natl Cancer Inst 2020 ; Guarneri V et al., Clin Cancer Res 2020 ; Griguolo G et al., Cancers 2020 ; Prat A et al., Lancet Oncol 2020 ; Griguolo G et al., J Immunother Cancer 2019 ; Guarneri V et al., Ann Oncol 2019).

- Collaboration with the Institut Régional du Cancer de Montpellier (ICM) and Montefiore Medical Center Bronx New York: analysis of immune biomarkers in brain metastases from breast cancer (Griguolo et al., ASCO 2020).

3. PUBLICATIONS

Dr. Dieci is first or co-author of 98 publications published in peer-reviewed international journals.

Total impact factor (JCR 2020): 1047.041.

H-index (July 2021, Scopus): 28

Total citations (July 2021, Scopus): 3350

Author or co-author of 8 book chapters.

3.1 Publications in peer-reviewed journals

1. Miglietta F, Griguolo G, Bottosso M, Giarratano T, Lo Mele M, Fassan M, Cacciatore M, Genovesi E, De Bartolo D, Vernaci G, Amato O, Conte P, Guarneri V, **Dieci MV**. HER2-low evolution from primary breast cancer to relapse. NPJ Breast Cancer. 2021. In press.
2. **Dieci MV**, Griguolo G, Bottosso M, Tsvetkova V, Giorgi CA, Vernaci G, Michieletto S, Angelini S, Marchet A, Tasca G, Genovesi E, Cumerlato E, Lo Mele M, Conte P, Guarneri V. Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy. NPJ Breast Cancer. 2021. In press.
3. **Dieci MV**, Miglietta F. HER2: a never ending story. Lancet Oncol. 2021 Jul 9:S1470-2045(21)00349-1. doi: 10.1016/S1470-2045(21)00349-1. Epub ahead of print. PMID: 34252373.
4. Guarneri V, Giorgi CA, Cinieri S, Bengala C, Mariani G, Bisagni G, Frassoldati A, Zamagni C, De Rossi C, Amoroso V, Andreetta C, Ferro A, Zambelli A, Gori S, Garrone O, **Dieci MV**, Orlando L, Pastina I, Beninato T, Moretti G, Genovesi E, Cinefra M, Vicini R, Magni G, De Salvo GL, Conte P. Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINTenance Afinitor) trial. Eur J Cancer. 2021 Jul 2;154:21-29. doi: 10.1016/j.ejca.2021.05.008. Epub ahead of print. PMID: 34225066.
5. Guarneri V, **Dieci MV**, Griguolo G, Miglietta F, Girardi F, Bisagni G, Generali DG, Cagossi K, Sarti S, Frassoldati A, Gianni L, Cavanna L, Pinotti G, Musolino A, Piacentini F, Cinieri S, Prat A, Conte P; of the CHER-Lob study team. Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial. Eur J Cancer. 2021 Aug;153:133-141. doi: 10.1016/j.ejca.2021.05.018. Epub 2021 Jun 19. PMID: 34153715.
6. Miglietta F, **Dieci MV**, Griguolo G, Guarneri V. Neoadjuvant approach as a platform for treatment personalization: focus on HER2-positive and triple-negative breast cancer. Cancer Treat Rev. 2021 Jul;98:102222. doi: 10.1016/j.ctrv.2021.102222. Epub 2021 May 12. PMID: 34023642.
7. Rinnerthaler G, Müller V, Balic M, Zaman K, **Dieci MV**. Expert Discussion: Immunotherapy in Breast Cancer - Ready for Prime Time? Breast Care (Basel). 2021 Apr;16(2):188-191. doi: 10.1159/000515746. Epub 2021 Mar 26. PMID: 34012374; PMCID: PMC8114073.
8. Pascual T, Fernandez-Martinez A, Tanioka M, **Dieci MV**, Pernas P, Gavilá J, Guarneri V, Cortés J, Villagrana P, Chic N, Vidal M, Adamo B, Muñoz M, Griguolo G, Llombart-Cussac A, Conte PF, Oliveira M, Conte B, Paré L, Galván P, Carey LA, Perou CM, Prat A. Independent validation of the PAM50-based Chemo-Endocrine Score in hormonal receptor positive HER2-positive breast cancer treated with neoadjuvant therapy. Clin Cancer Res. 2021 Feb 25; clincanres.4102.2020. doi:10.1158/1078-0432.CCR-20-4102; PMID: 33632929. Online ahead of print.
9. Solinas C, Fumagalli D, **Dieci MV**. Immune checkpoint blockade in HER2-positive breast cancer: what role in early disease setting? Cancers 2021, 13(7):1655. doi:10.3390/cancers13071655
10. Urso L, Vernaci G, Carlet J, Lo Mele M, Fassan M, Zulato E, Faggioni G, Menichetti A, Di Liso E, Griguolo G, Falcu C, Conte PF, Indraccolo S, Guarneri V, **Dieci MV**. ESR1 gene mutation in hormone receptor-positive HER2-negative metastatic breast cancer patients: concordance between tumor tissue and

- circulating tumor DNA analysis. *Front Oncol.* 2021 Mar 11;11:625636. doi: 10.3389/fonc.2021.625636. PMID: 33777770; PMCID: PMC7991720.
11. **Dieci MV**, Miglietta F, Guarneri V. Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications. *Cells.* 2021 Jan 23;10(2):223. doi: 10.3390/cells10020223. PMID: 33498711.
 12. Guarneri V, Bassan F, Zagonel V, Milella M, Zaninelli M, Cattelan AM, Vianello A, Gori S, Aprile G, Azzarello G, Chiari R, Favaretto A, Oliani C, Scola A, Pastorelli D, Mandarà M, Zustovich F, Bernardi D, Chiarion-Sileni V, Morandi P, Toso S, Di Liso E, Ziampiri S, Caccese M, Zampiva I, Puccetti O, Celestino M, **Dieci MV**, Conte PF. Epidemiology and clinical course of SARS-CoV-2 infection in cancer patients in the Veneto Oncology Network: The ROVID Study. *Eur J Cancer.* 2021 Apr;147:120-127. doi: 10.1016/j.ejca.2021.01.021. Epub 2021 Feb 3. PMID: 33647547; PMCID: PMC7857033.
 13. Griguolo G, **Dieci MV**, Paré L, Miglietta F, Generali DG, Frassoldati A, Cavanna L, Bisagni G, Piacentini F, Tagliafico E, Cagossi K, Ficarra G, Prat A, Conte PF, Guarneri V. Immune microenvironment and intrinsic subtyping in hormone-receptor-positive/HER2-negative breast cancer. *NPJ Breast Cancer.* 2021 Feb 12;7(1):12. doi: 10.1038/s41523-021-00223-x. PMID: 33579951; PMCID: PMC7881184.
 14. Matteo Lambertini, Marcello Ceppi, Anne-Sophie Hamy, Olivier Caron, Philip Poorvu, Estela Carrasco, Albert Grinshpun, Kevin Punie, Christine Rousset-Jablonski, Alberta Ferrari, Shani Paluch-Shimon, Angela Toss, Claire Senechal, Fabio Puglisi, Katarzyna Pogoda, Jose Alejandro Pérez-Fidalgo, Laura De Marchis De Marchis, Riccardo Ponzzone, Luca Livraghi, Maria Del Pilar Estevez-Diz, Cynthia Villarreal-Garza, **Maria Vittoria Dieci**, Florian Clatot, Francois Duhoux, Rossella Graffeo, Luis Teixeira, Octavi Cordoba, Amir Sonnenblick, Arlindo Ferreira, Ann H Partridge, Antonio Di Meglio, Claire Saule, Fedro Peccatori, Marco Bruzzone, Marie Daphne t'Kint de Roodenbeke, Lieveke Ameye, Judith Balmaña, Lucia Del Mastro, and Hatem Azim. Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants. *NPJ Breast Cancer.* 2021 Feb 12;7(1):16. doi: 10.1038/s41523-021-00224-w. PMID: 33579978; PMCID: PMC7880991.
 15. Vernaci G, Meroni M, **Dieci MV**, Saibene T, Montesco MC, Orvieto E, Cattelan AM, Ghiotto C, Miglietta F, Guarneri V, Cagol M. Post-surgical pyoderma gangrenosum in a breast cancer patient: a case report and literature review. *Case Rep Oncol.* 2021 Mar 1;14(1):160-164. doi: 10.1159/000509745. PMID: 33776698; PMCID: PMC7983549.
 16. Tasca G, **Dieci MV**, Baretta Z, Faggioni G, Montagna M, Nicoletto MO, Peccatori FA, Guarneri V, Colombo N. Synchronous and Metachronous Breast and Ovarian Cancer: Experience From Two Large Cancer Center. *Front Oncol.* 2020 Dec 14;10:608783. doi: 10.3389/fonc.2020.608783. PMID: 33381461; PMCID: PMC7768039
 17. Celotto F, Tropea S, Rastrelli M, Saibene T, Gazzetta G, **Dieci MV**, Scapinello A, Michieletto S. Solitary biceps muscle metastasis from neuroendocrine breast tumor. *Breast J.* 2021 Feb;27(2):185-187. doi: 10.1111/tbj.14139. Epub 2020 Dec 22. PMID: 33350531.
 18. Prat A, Guarneri V, Paré L, Griguolo G, Pascual T, **Dieci MV**, Chic N, González-Farré B, Frassoldati A, Sanfeliu E, Cejalvo JM, Muñoz M, Bisagni G, Brasó-Maristany F, Urso L, Vidal M, Brandes AA, Adamo B, Musolino A, Miglietta F, Conte B, Oliveira M, Saura C, Pernas S, Alarcón J, Llombart-Cussac A, Cortés J, Manso L, López R, Ciruelos E, Schettini F, Villagrana P, Carey LA, Perou CM, Piacentini F, D'Amico R, Tagliafico E, Parker JS, Conte P. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. *Lancet Oncol.* 2020 Nov;21(11):1455-1464. doi: 10.1016/S1470-2045(20)30450-2. PMID: 33152285.
 19. Zarrilli G, Businello G, **Dieci MV**, Paccagnella S, Carraro V, Cappellesso R, Miglietta F, Griguolo G, Guarneri V, Lo Mele M, Fassan M. The Tumor Microenvironment of Primitive and Metastatic Breast Cancer: Implications for Novel Therapeutic Strategies. *Int J Mol Sci.* 2020 Oct 30;21(21):8102. doi: 10.3390/ijms21218102. PMID: 33143050; PMCID: PMC7662409.
 20. **Dieci MV**, Guarneri V. Should triple-positive breast cancer be recognized as a distinct subtype? *Expert Rev Anticancer Ther.* 2020 Dec;20(12):1011-1014. doi: 10.1080/14737140.2020.1829484. Epub 2020 Oct 6. PMID: 33021124.

21. Di Liso E, Bottosso M, Lo Mele M, Tsvetkova V, **Dieci MV**, Miglietta F, Falci C, Faggioni G, Tasca G, Giorgi CA, Giarratano T, Mioranza E, Michieletto S, Saibene T, Dei Tos AP, Conte P, Guarneri V. Prognostic factors in phyllodes tumours of the breast: retrospective study on 166 consecutive cases. *ESMO Open*. 2020 Oct;5(5):e000843. doi: 10.1136/esmooopen-2020-000843. PMID: 33020219; PMCID: PMC7537333.
22. Guarneri V, **Dieci MV**, Bisagni G, Brandes AA, Frassoldati A, Cavanna L, Musolino A, Giotta F, Rimanti A, Garrone O, Bertone E, Cagossi K, Nanni O, Piacentini F, Orvieto E, Griguolo G, Curtarello M, Urso L, Paré L, Chic N, D'Amico R, Prat A, Conte P. *PIK3CA* Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2⁺ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype. *Clin Cancer Res*. 2020 Nov 15;26(22):5843-5851. doi: 10.1158/1078-0432.CCR-20-1731. Epub 2020 Aug 25. PMID: 32843527.
23. Griguolo G, Brasó-Maristany F, González-Farré B, Pascual T, Chic N, Saurí T, Kates R, Gluz O, Martínez D, Paré L, Tsvetkova V, Pesantez D, Vidal M, Adamo B, Muñoz M, Galván P, Barberá L, Cuatrecasas M, Christgen M, Kreipe H, Monge-Escartín I, Villagrana P, Soy D, Giarratano T, **Dieci MV**, Conte P, Harbeck N, Guarneri V, Prat A. *ERBB2* mRNA Expression and Response to Ado-Trastuzumab Emtrastine (T-DM1) in HER2-Positive Breast Cancer. *Cancers (Basel)*. 2020 Jul 14;12(7):1902. doi: 10.3390/cancers12071902. PMID: 32674482; PMCID: PMC7409149.
24. Lambertini M, Ameye L, Hamy AS, Zingarello A, Poorvu PD, Carrasco E, Grinshpun A, Han S, Rousset-Jablonski C, Ferrari A, Paluch-Shimon S, Cortesi L, Senechal C, Miolo G, Pogoda K, Pérez-Fidalgo JA, De Marchis L, Ponzzone R, Livraghi L, Estevez-Diz MDP, Villarreal-Garza C, **Dieci MV**, Clatot F, Berlière M, Graffeo R, Teixeira L, Córdoba O, Sonnenblick A, Luna Pais H, Ignatiadis M, Paesmans M, Partridge AH, Caron O, Saule C, Del Mastro L, Peccatori FA, Azim HA Jr. Pregnancy After Breast Cancer in Patients With Germline *BRCA* Mutations. *J Clin Oncol*. 2020 Sep 10;38(26):3012-3023. doi: 10.1200/JCO.19.02399. Epub 2020 Jul 16. PMID: 32673153.
25. **Dieci MV**, Tsvetkova V, Griguolo G, Miglietta F, Tasca G, Giorgi CA, Cumerlato E, Massa D, Lo Mele M, Orvieto E, Guarneri V, Conte P. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy. *Eur J Cancer*. 2020 Sep;136:7-15. doi: 10.1016/j.ejca.2020.05.014. Epub 2020 Jul 1. PMID: 32622323.
26. **Dieci MV**, Miglietta F, Griguolo G, Guarneri V. Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors. *Cancer Treat Rev*. 2020 Aug;88:102064. doi: 10.1016/j.ctrv.2020.102064. Epub 2020 Jun 24. PMID: 32622272.
27. Miglietta F, **Dieci MV**, Tsvetkova V, Griguolo G, Vernaci G, Menichetti A, Faggioni G, Giarratano T, Mioranza E, Genovesi E, Cumerlato E, Bottosso M, Saibene T, Michieletto S, Lo Mele M, Conte P, Guarneri V. Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer. *Oncologist*. 2020 Sep;25(9):e1355-e1362. doi: 10.1634/theoncologist.2020-0201. Epub 2020 Jul 21. PMID: 32618068; PMCID: PMC7485331.
28. Kos Z, Roblin E, Kim RS, Michiels S, Gallas BD, Chen W, van de Vijver KK, Goel S, Adams S, Demaria S, Viale G, Nielsen TO, Badve SS, Symmans WF, Sotiriou C, Rimm DL, Hewitt S, Denkert C, Loibl S, Luen SJ, Bartlett JMS, Savas P, Pruneri G, Dillon DA, Cheang MCU, Tutt A, Hall JA, Kok M, Horlings HM, Madabhushi A, van der Laak J, Ciompi F, Laenkholm AV, Bellolio E, Grusso T, Fox SB, Araya JC, Floris G, Hudeček J, Voorwerk L, Beck AH, Kerner J, Larsimont D, Declercq S, Van den Eynden G, Pusztai L, Ehinger A, Yang W, AbdulJabbar K, Yuan Y, Singh R, Hiley C, Bakir MA, Lazar AJ, Naber S, Wienert S, Castillo M, Curigliano G, **Dieci MV**, André F, Swanton C, Reis-Filho J, Sparano J, Balslev E, Chen IC, Stovgaard EIS, Pogue-Geile K, Blenman KRM, Penault-Llorca F, Schnitt S, Lakhani SR, Vincent-Salomon A, Rojo F, Braybrooke JP, Hanna MG, Soler-Monsó MT, Bethmann D, Castaneda CA, Willard-Gallo K, Sharma A, Lien HC, Fineberg S, Thagaard J, Comerma L, Gonzalez-Ericsson P, Brogi E, Loi S, Saltz J, Klausner F, Cooper L, Amgad M, Moore DA, Salgado R; International Immuno-Oncology Biomarker Working Group. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. *NPJ Breast Cancer*. 2020 May 12;6:17. doi: 10.1038/s41523-020-0156-0. PMID: 32411819; PMCID: PMC7217863.

29. Griguolo G, **Dieci MV**, Miglietta F, Guarneri V, Conte P. Olaparib for advanced breast cancer. *Future Oncol.* 2020 Apr;16(12):717-732. doi: 10.2217/fon-2019-0689. Epub 2020 Apr 6. PMID: 32249603.
30. Lambertini M, Toss A, Passaro A, Criscitiello C, Cremolini C, Cardone C, Loupakis F, Viscardi G, Meattini I, **Dieci MV**, Ferrara R, Giusti R, Maio MD. Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists' perspective. *ESMO Open.* 2020 Mar;5(2):e000759. doi: 10.1136/esmoopen-2020-000759. PMID: 32229501; PMCID: PMC7174009.
31. Gonzalez-Ericsson PI, Stovgaard ES, Sua LF, Reisenbichler E, Kos Z, Carter JM, Michiels S, Le Quesne J, Nielsen TO, Laenkholm AV, Fox SB, Adam J, Bartlett JM, Rimm DL, Quinn C, Peeters D, **Dieci MV**, Vincent-Salomon A, Cree I, Hida AI, Balko JM, Haynes HR, Frahm I, Acosta-Haab G, Balancin M, Bellolio E, Yang W, Kirtani P, Sugie T, Ehinger A, Castaneda CA, Kok M, McArthur H, Siziopikou K, Badve S, Fineberg S, Gown A, Viale G, Schnitt SJ, Pruneri G, Penault-Llorca F, Hewitt S, Thompson EA, Allison KH, Symmans WF, Bellizzi AM, Brogi E, Moore DA, Larsimont D, Dillon DA, Lazar A, Lien H, Goetz MP, Broeckx G, El Bairi K, Harbeck N, Cimino-Mathews A, Sotiriou C, Adams S, Liu SW, Loibl S, Chen IC, Lakhani SR, Juco JW, Denkert C, Blackley EF, Demaria S, Leon-Ferre R, Gluz O, Zardavas D, Emancipator K, Ely S, Loi S, Salgado R, Sanders M; International Immuno-Oncology Biomarker Working Group. The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice. *J Pathol.* 2020 Apr;250(5):667-684. doi: 10.1002/path.5406. Epub 2020 Apr 9. PMID: 32129476.
32. Carbognin L, Simbolo M, Calìò A, Vicentini C, Delfino P, Sperduti I, Fassan M, Schettini F, **Dieci MV**, Griguolo G, Pilotto S, Fiorio E, Arpino G, Guarneri V, De Placido S, Conte P, Manfrin E, Brunelli M, Scambia G, Scarpa A, Tortora G, Bria E. Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model. *Breast.* 2020 Apr;50:56-63. doi: 10.1016/j.breast.2020.01.034. Epub 2020 Jan 27. PMID: 32028173; PMCID: PMC7375560.
33. Giarratano T, Frezzini S, Zanocco M, Giorgi CA, Mioranza E, Miglietta F, Griguolo G, Falci C, Faggioni G, Tasca G, Di Liso E, Vernaci G, Menichetti A, Mantiero M, Grosso D, Guarneri V, **Dieci MV**. Use of scalp cooling device to prevent alopecia for early breast cancer patients receiving chemotherapy: A prospective study. *Breast J.* 2020 Jul;26(7):1296-1301. doi: 10.1111/tbj.13711. Epub 2019 Dec 14. PMID: 31837103.
34. **Dieci MV**, Bisagni G, Brandes AA, Frassoldati A, Cavanna L, Giotta F, Aieta M, Gebbia V, Musolino A, Garrone O, Donadio M, Rimanti A, Beano A, Zamagni C, Soto Parra H, Piacentini F, Danese S, Ferro A, Cagossi K, Sarti S, Gambaro AR, Romito S, Bazan V, Amaducci L, Moretti G, Foschini MP, Balduzzi S, Vicini R, D'Amico R, Griguolo G, Guarneri V, Conte PF. Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial. *BMC Med.* 2019 Nov 21;17(1):207. doi: 10.1186/s12916-019-1445-z. PMID: 31747948; PMCID: PMC6868696.
35. Park JH, Jonas SF, Bataillon G, Criscitiello C, Salgado R, Loi S, Viale G, Lee HJ, **Dieci MV**, Kim SB, Vincent-Salomon A, Curigliano G, André F, Michiels S. Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy. *Ann Oncol.* 2019 Dec 1;30(12):1941-1949. doi: 10.1093/annonc/mdz395. PMID: 31566659.
36. Carbognin L, Miglietta F, Paris I, **Dieci MV**. Prognostic and Predictive Implications of PTEN in Breast Cancer: Unfulfilled Promises but Intriguing Perspectives. *Cancers (Basel).* 2019 Sep 19;11(9):1401. doi: 10.3390/cancers11091401. PMID: 31546901; PMCID: PMC6769721.
37. Miglietta F, Griguolo G, Guarneri V, **Dieci MV**. Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value. *Oncologist.* 2019 Nov;24(11):e1055-e1069. doi: 10.1634/theoncologist.2019-0197. Epub 2019 Aug 23. PMID: 31444294; PMCID: PMC6853089.
38. **Dieci MV**, Del Mastro L, Cinquini M, Montemurro F, Biganzoli L, Cortesi L, Zambelli A, Criscitiello C, Levaggi A, Conte B, Calabrese M, Fiorentino A, Marchiò C, Tinterri C, Fittipaldo VA, Pappagallo G, Gori S. Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medical Oncology (AIOM). *Cancers*

- (Basel). 2019 Aug 8;11(8):1137. doi: 10.3390/cancers11081137. PMID: 31398896; PMCID: PMC6721549.
39. Vernaci G, **Dieci MV**, Manfrin S, Mantiero M, Falci C, Faggioni G, Mioranza E, Menichetti A, Tasca G, Griguolo G, Miglietta F, Di Liso E, Saibene T, Michieletto S, Ghiotto C, Conte P, Guarneri V. BMI is an independent prognostic factor for late outcome in patients diagnosed with early breast cancer: A landmark survival analysis. *Breast*. 2019 Oct;47:77-84. doi: 10.1016/j.breast.2019.07.003. Epub 2019 Jul 20. PMID: 31357134.
 40. **Dieci MV**, Tsvetkova V, Griguolo G, Miglietta F, Mantiero M, Tasca G, Cumerlato E, Giorgi CA, Giarratano T, Faggioni G, Falci C, Vernaci G, Menichetti A, Mioranza E, Di Liso E, Frezzini S, Saibene T, Orvieto E, Guarneri V. Androgen Receptor Expression and Association With Distant Disease-Free Survival in Triple Negative Breast Cancer: Analysis of 263 Patients Treated With Standard Therapy for Stage I-III Disease. *Front Oncol*. 2019 Jun 6;9:452. doi: 10.3389/fonc.2019.00452. PMID: 31245286; PMCID: PMC6563384.
 41. **Dieci MV**, Guarneri V, Zustovich F, Mion M, Morandi P, Bria E, Merlini L, Bullian P, Oliani C, Gori S, Giarratano T, Orvieto E, Griguolo G, Michieletto S, Saibene T, Del Bianco P, De Salvo GL, Conte P; Veneto Oncology Network. Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study. *Oncologist*. 2019 Nov;24(11):1424-1431. doi: 10.1634/theoncologist.2019-0103. Epub 2019 May 31. PMID: 31152079; PMCID: PMC6853101.
 42. Campana LG, Miklavčič D, Bertino G, Marconato R, Valpione S, Imarisio I, **Dieci MV**, Granziera E, Cemazar M, Alaibac M, Sersa G. Electrochemotherapy of superficial tumors - Current status:: Basic principles, operating procedures, shared indications, and emerging applications. *Semin Oncol*. 2019 Apr;46(2):173-191. doi: 10.1053/j.seminoncol.2019.04.002. Epub 2019 May 9. PMID: 31122761.
 43. Prat A, Pascual T, De Angelis C, Gutierrez C, Llombart-Cussac A, Wang T, Cortés J, Rexer B, Paré L, Forero A, Wolff AC, Morales S, Adamo B, Brasó-Maristany F, Vidal M, Veeraraghavan J, Krop I, Galván P, Pavlick AC, Bermejo B, Izquierdo M, Rodrik-Outmezguine V, Reis-Filho JS, Hilsenbeck SG, Oliveira M, **Dieci MV**, Griguolo G, Fasani R, Nuciforo P, Parker JS, Conte P, Schiff R, Guarneri V, Osborne CK, Rimawi MF. HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. *J Natl Cancer Inst*. 2020 Jan 1;112(1):46-54. doi: 10.1093/jnci/djz042. PMID: 31037288; PMCID: PMC7850037.
 44. Griguolo G, Pascual T, **Dieci MV**, Guarneri V, Prat A. Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer. *J Immunother Cancer*. 2019 Mar 29;7(1):90. doi: 10.1186/s40425-019-0548-6. PMID: 30922362; PMCID: PMC6439986.
 45. Di Liso E, Menichetti A, **Dieci MV**, Ghiotto C, Banzato A, Bianchi A, Pintacuda G, Padovan M, Nappo F, Cumerlato E, Miglietta F, Mioranza E, Zago G, Corti L, Guarneri V, Conte P. Neoplastic Pericardial Effusion: A Monocentric Retrospective Study. *J Palliat Med*. 2019 Jun;22(6):691-695. doi: 10.1089/jpm.2018.0491. Epub 2019 Mar 19. PMID: 30888908.
 46. Guarneri V, **Dieci MV**, Bisagni G, Frassoldati A, Bianchi GV, De Salvo GL, Orvieto E, Urso L, Pascual T, Paré L, Galván P, Ambroggi M, Giorgi CA, Moretti G, Griguolo G, Vicini R, Prat A, Conte PF. De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study. *Ann Oncol*. 2019 Jun 1;30(6):921-926. doi: 10.1093/annonc/mdz055. PMID: 30778520; PMCID: PMC6594455.
 47. **Dieci MV**, Conte P, Bisagni G, Brandes AA, Frassoldati A, Cavanna L, Musolino A, Giotta F, Rimanti A, Garrone O, Bertone E, Cagossi K, Sarti S, Ferro A, Piacentini F, Maiorana A, Orvieto E, Sanders M, Miglietta F, Balduzzi S, D'Amico R, Guarneri V. Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. *Ann Oncol*. 2019 Mar 1;30(3):418-423. doi: 10.1093/annonc/mdz007. PMID: 30657852; PMCID: PMC6442655.
 48. Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, **Dieci MV**, Badve S, Demaria S, Gray R, Munzone E, Lemonnier J, Sotiriou C, Piccart MJ, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, Andre F, Denkert C, Salgado R, Michiels S. Tumor-Infiltrating Lymphocytes and Prognosis:

- A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. *J Clin Oncol*. 2019 Mar 1;37(7):559-569. doi: 10.1200/JCO.18.01010. Epub 2019 Jan 16. PMID: 30650045; PMCID: PMC7010425.
49. Luen SJ, Salgado R, **Dieci MV**, Vingiani A, Curigliano G, Gould RE, Castaneda C, D'Alfonso T, Sanchez J, Cheng E, Andreopoulou E, Castillo M, Adams S, Demaria S, Symmans WF, Michiels S, Loi S. Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy. *Ann Oncol*. 2019 Feb 1;30(2):236-242. doi: 10.1093/annonc/mdy547. PMID: 30590484. Giarratano T, Miglietta F, Giorgi CA, Tsvetkova V, Michieletto S, Evangelista L, Polico I, **Dieci MV**, Guarneri V. Exceptional and Durable Responses to TDM-1 After Trastuzumab Failure for Breast Cancer Skin Metastases: Potential Implications of an Immunological Sanctuary. *Front Oncol*. 2018 Dec 3;8:581. doi: 10.3389/fonc.2018.00581. PMID: 30560092; PMCID: PMC6287048.
 50. **Dieci MV**, Massari F, Giusti R, Inno A, Lombardi G, Noto L, Passaro A, Pietrantonio F, Spada F, Valente M, Di Maio M, Torri V. Gender influence on professional satisfaction and gender issue perception among young oncologists. A survey of the Young Oncologists Working Group of the Italian Association of Medical Oncology (AIOM). *ESMO Open*. 2018 Oct 21;3(6):e000389. doi: 10.1136/esmoopen-2018-000389. PMID: 30425842; PMCID: PMC6212682.
 51. **Dieci MV**, Vernaci G, Guarneri V. Escalation and de-escalation in HER2 positive early breast cancer. *Curr Opin Oncol*. 2019 Jan;31(1):35-42. doi: 10.1097/CCO.0000000000000492. PMID: 30325338.
 52. Griguolo G, Pouderoux S, **Dieci MV**, Jacot W, Bourgier C, Miglietta F, Firmin N, Conte P, Viala M, Guarneri V, Darlix A. Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology. *Oncologist*. 2018 Nov;23(11):1289-1299. doi: 10.1634/theoncologist.2018-0200. Epub 2018 Aug 17. PMID: 30120164; PMCID: PMC6291333.
 53. Bonanno L, Pavan A, **Dieci MV**, Di Liso E, Schiavon M, Comacchio G, Attili I, Pasello G, Calabrese F, Rea F, Favaretto A, Ruge M, Guarneri V, Fassan M, Conte PF. The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes. *Eur J Cancer*. 2018 Sep;101:191-200. doi: 10.1016/j.ejca.2018.06.023. Epub 2018 Aug 1. PMID: 30077124.
 54. **Dieci MV**, Ghiotto C, Barbieri C, Griguolo G, Saccardi C, Gangemi M, Pluchinotta A, Di Liso E, Giorgi CA, Giarratano T, Tasca G, Vernaci G, Faggioni G, Conte P, Guarneri V. Patterns of Fertility Preservation and Pregnancy Outcome After Breast Cancer at a Large Comprehensive Cancer Center. *J Womens Health (Larchmt)*. 2019 Apr;28(4):544-550. doi: 10.1089/jwh.2018.6986. Epub 2018 Jul 2. PMID: 29963941; PMCID: PMC6482901.
 55. **Dieci MV**, Tsvetkova V, Orvieto E, Piacentini F, Ficarra G, Griguolo G, Miglietta F, Giarratano T, Omarini C, Bonaguro S, Cappellesso R, Aliberti C, Vernaci G, Giorgi CA, Faggioni G, Tasca G, Conte P, Guarneri V. Immune characterization of breast cancer metastases: prognostic implications. *Breast Cancer Res*. 2018 Jun 22;20(1):62. doi: 10.1186/s13058-018-1003-1. PMID: 29929548; PMCID: PMC6013851.
 56. Griguolo G, **Dieci MV**, Guarneri V, Conte P. Olaparib for the treatment of breast cancer. *Expert Rev Anticancer Ther*. 2018 Jun;18(6):519-530. doi: 10.1080/14737140.2018.1458613. Epub 2018 Mar 30. PMID: 29582690.
 57. Darlix A, Griguolo G, Thezenas S, Kantelhardt E, Thomssen C, **Dieci MV**, Miglietta F, Conte P, Braccini AL, Ferrero JM, Bailleux C, Jacot W, Guarneri V. Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer. *J Neurooncol*. 2018 Jun;138(2):369-382. doi: 10.1007/s11060-018-2805-9. Epub 2018 Feb 27. PMID: 29488184.
 58. **Dieci MV**, Guarneri V, Giarratano T, Mion M, Tortora G, De Rossi C, Gori S, Oliani C, Merlini L, Pasini F, Bonciarelli G, Griguolo G, Orvieto E, Michieletto S, Saibene T, Del Bianco P, De Salvo GL, Conte P. First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer. *Oncologist*. 2018 Mar;23(3):297-305. doi: 10.1634/theoncologist.2017-0322. Epub 2017 Nov 13. PMID: 29133514; PMCID: PMC5905682.

59. Griguolo G, Jacot W, Kantelhardt E, **Dieci MV**, Bourgier C, Thomssen C, Bailleux C, Miglietta F, Braccini AL, Conte P, Ferrero JM, Guarneri V, Darlix A. External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experience. *Breast*. 2018 Feb;37:36-41. doi: 10.1016/j.breast.2017.10.006. Epub 2017 Oct 23. PMID: 29073498.
60. **Dieci MV**, Radosevic-Robin N, Fineberg S, van den Eynden G, Ternes N, Penault-Llorca F, Pruneri G, D'Alfonso TM, Demaria S, Castaneda C, Sanchez J, Badve S, Michiels S, Bossuyt V, Rojo F, Singh B, Nielsen T, Viale G, Kim SR, Hewitt S, Wienert S, Loibl S, Rimm D, Symmans F, Denkert C, Adams S, Loi S, Salgado R; International Immuno-Oncology Biomarker Working Group on Breast Cancer. Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. *Semin Cancer Biol*. 2018 Oct;52(Pt 2):16-25. doi: 10.1016/j.semcancer.2017.10.003. Epub 2017 Oct 9. PMID: 29024776.
61. Miglietta F, **Dieci MV**, Griguolo G, Guarneri V, Conte PF. Chemotherapy for advanced HER2-negative breast cancer: Can one algorithm fit all? *Cancer Treat Rev*. 2017 Nov;60:100-108. doi: 10.1016/j.ctrv.2017.09.001. Epub 2017 Sep 15. PMID: 28942029.
62. Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, **Dieci MV**, Urbanowicz M, Brcic I, Korski K, Gaire F, Koepfen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. *Adv Anat Pathol*. 2017 Nov;24(6):311-335. doi: 10.1097/PAP.000000000000161. PMID: 28777143; PMCID: PMC5638696.
63. Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, **Dieci MV**, Urbanowicz M, Brcic I, Korski K, Gaire F, Koepfen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB. Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. *Adv Anat Pathol*. 2017 Sep;24(5):235-251. doi: 10.1097/PAP.000000000000162. PMID: 28777142; PMCID: PMC5564448.

64. Banna GL, Parra HJS, Castaing M, **Dieci MV**, Anile G, Nicolosi M, Strano S, Marletta F, Guarneri V, Conte P, Lal R. Histology-based Combination Induction Chemotherapy for Elderly Patients with Clinical Stage III Non-small Cell Lung Cancer. *Anticancer Res.* 2017 Jul;37(7):3723-3728. doi: 10.21873/anticancer.11745. PMID: 28668866.
65. Carbognin L, Sperduti I, Fabi A, **Dieci MV**, Kadrija D, Griguolo G, Pilotto S, Guarneri V, Zampiva I, Brunelli M, Orvieto E, Nortilli R, Fiorio E, Parolin V, Manfrin E, Caliò A, Nisticò C, Pellini F, Scarpa A, Pollini GP, Conte P, Tortora G, Bria E. Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation. *Breast.* 2017 Oct;35:21-26. doi: 10.1016/j.breast.2017.06.005. Epub 2017 Jun 17. PMID: 28628772.
66. Orsi G, Barbolini M, Ficarra G, Tazzioli G, Manni P, Petrachi T, Mastrolia I, Orvieto E, Spano C, Prapa M, Kaleci S, D'Amico R, Guarneri V, **Dieci MV**, Cascinu S, Conte P, Piacentini F, Dominici M. GD2 expression in breast cancer. *Oncotarget.* 2017 May 9;8(19):31592-31600. doi: 10.18632/oncotarget.16363. PMID: 28415563; PMCID: PMC5458232.
67. **Dieci MV**, Frassoldati A, Generali D, Bisagni G, Piacentini F, Cavanna L, Cagossi K, Puglisi F, Michelotti A, Berardi R, Banna G, Goubar A, Ficarra G, Griguolo G, Conte P, Guarneri V. Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials. *Breast Cancer Res Treat.* 2017 Jun;163(2):295-302. doi: 10.1007/s10549-017-4191-y. Epub 2017 Mar 13. Erratum in: *Breast Cancer Res Treat.* 2017 Jun;163(3):637. PMID: 28289852.
68. Lefebvre C, Bachelot T, Filleron T, Pedrero M, Campone M, Soria JC, Massard C, Lévy C, Arnedos M, Lacroix-Triki M, Garrabey J, Boursin Y, Deloger M, Fu Y, Commo F, Scott V, Lacroix L, **Dieci MV**, Kamal M, Diéras V, Gonçalves A, Ferrero JM, Romieu G, Vanlemmens L, Mouret Reynier MA, Théry JC, Le Du F, Guiu S, Dalenc F, Clapison G, Bonnefoi H, Jimenez M, Le Tourneau C, André F. Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis. *PLoS Med.* 2016 Dec 27;13(12):e1002201. doi: 10.1371/journal.pmed.1002201. PMID: 28027327; PMCID: PMC5189935.
69. Griguolo G, **Dieci MV**, Giarratano T, Giorgi CA, Orvieto E, Ghiotto C, Berti F, Della Puppa A, Falci C, Mioranza E, Tasca G, Milite N, Miglietta F, Scienza R, Conte P, Guarneri V. Beyond breast specific-Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcome. *J Neurooncol.* 2017 Jan;131(2):369-376. doi: 10.1007/s11060-016-2309-4. Epub 2016 Nov 16. PMID: 27853958.
70. **Dieci MV**, Prat A, Tagliafico E, Paré L, Ficarra G, Bisagni G, Piacentini F, Generali DG, Conte P, Guarneri V. Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial. *Ann Oncol.* 2016 Oct;27(10):1867-73. doi: 10.1093/annonc/mdw262. Epub 2016 Aug 2. PMID: 27484801.
71. Musolino A, Naldi N, **Dieci MV**, Zanoni D, Rimanti A, Boggiani D, Sgargi P, Generali DG, Piacentini F, Ambroggi M, Cagossi K, Gianni L, Sarti S, Bisagni G, Ardizzoni A, Conte PF, Guarneri V. Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer. *Pharmacogenomics J.* 2016 Oct;16(5):472-7. doi: 10.1038/tpj.2016.51. Epub 2016 Jul 5. PMID: 27378608.
72. Gennari R, Griguolo G, **Dieci MV**, Guarneri V, Tavaniello B, Sibilio A, Conte P. Fat grafting for breast cancer patients: From basic science to clinical studies. *Eur J Surg Oncol.* 2016 Aug;42(8):1088-102. doi: 10.1016/j.ejso.2016.04.062. Epub 2016 May 27. PMID: 27265042
73. **Dieci MV**, Griguolo G, Miglietta F, Guarneri V. The immune system and hormone-receptor positive breast cancer: Is it really a dead end? *Cancer Treat Rev.* 2016 May;46:9-19. doi: 10.1016/j.ctrv.2016.03.011. Epub 2016 Mar 28. PMID: 27055087.
74. **Dieci MV**, Smutná V, Scott V, Yin G, Xu R, Vielh P, Mathieu MC, Vicier C, Laporte M, Drusch F, Guarneri V, Conte P, Delalogue S, Lacroix L, Fromigué O, André F, Lefebvre C. Whole exome sequencing of rare aggressive breast cancer histologies. *Breast Cancer Res Treat.* 2016 Feb;156(1):21-32. doi: 10.1007/s10549-016-3718-y. Epub 2016 Feb 23. PMID: 26907767.
75. Guarneri V, **Dieci MV**, Frassoldati A, Maiorana A, Ficarra G, Bettelli S, Tagliafico E, Bicciato S, Generali DG, Cagossi K, Bisagni G, Sarti S, Musolino A, Ellis C, Crescenzo R, Conte P. Prospective Biomarker Analysis of the Randomized ChER-LOB Study Evaluating the Dual Anti-HER2 Treatment With

- Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer. *Oncologist*. 2015 Sep;20(9):1001-10. doi: 10.1634/theoncologist.2015-0138. Epub 2015 Aug 5. PMID: 26245675; PMCID: PMC4571802.
76. **Dieci MV**, Mathieu MC, Guarneri V, Conte P, Delalogue S, Andre F, Goubar A. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. *Ann Oncol*. 2015 Aug;26(8):1698-704. doi: 10.1093/annonc/mdv239. Epub 2015 May 20. PMID: 25995301; PMCID: PMC4511223.
 77. Guarneri V, **Dieci MV**, Bisagni G, Boni C, Cagossi K, Puglisi F, Pecchi A, Piacentini F, Conte P. Preoperative carboplatin-paclitaxel-bevacizumab in triple-negative breast cancer: final results of the phase II Ca.Pa.Be study. *Ann Surg Oncol*. 2015 Sep;22(9):2881-7. doi: 10.1245/s10434-015-4371-0. Epub 2015 Jan 9. PMID: 25572687.
 78. Vicier C, **Dieci MV**, Arnedos M, Delalogue S, Viens P, Andre F. Clinical development of mTOR inhibitors in breast cancer. *Breast Cancer Res*. 2014 Feb 17;16(1):203. doi: 10.1186/bcr3618. PMID: 25189767; PMCID: PMC3978635.
 79. **Dieci MV**, Piacentini F, Dominici M, Omarini C, Goubar A, Ficarra G, Conte P, Guarneri V. Quantitative expression of estrogen receptor on relapse biopsy for ER-positive breast cancer: prognostic impact. *Anticancer Res*. 2014 Jul;34(7):3657-62. PMID: 24982383.
 80. **Dieci MV**, Orvieto E, Dominici M, Conte P, Guarneri V. Rare breast cancer subtypes: histological, molecular, and clinical peculiarities. *Oncologist*. 2014 Aug;19(8):805-13. doi: 10.1634/theoncologist.2014-0108. Epub 2014 Jun 26. PMID: 24969162; PMCID: PMC4122475.
 81. Falci C, **Dieci MV**, Guarneri V, Soldà C, Bria E, Tortora G, Conte P. Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents. *Expert Rev Anticancer Ther*. 2014 Sep;14(9):1041-50. doi: 10.1586/14737140.2014.922415. Epub 2014 Jun 23. PMID: 24953376.
 82. **Dieci MV**, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, Ficarra G, Mathieu MC, Delalogue S, Curigliano G, Andre F. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. *Ann Oncol*. 2014 Mar;25(3):611-618. doi: 10.1093/annonc/mdt556. Epub 2014 Jan 8. Erratum in: *Ann Oncol*. 2015 Jul;26(7):1518. PMID: 24401929; PMCID: PMC3933248.
 83. Vicier C, **Dieci MV**, Andre F. New strategies to overcome resistance to mammalian target of rapamycin inhibitors in breast cancer. *Curr Opin Oncol*. 2013 Nov;25(6):587-93. doi: 10.1097/CCO.000000000000014. PMID: 24097108.
 84. **Dieci MV**, Arnedos M, Delalogue S, Andre F. Quantification of residual risk of relapse in breast cancer patients optimally treated. *Breast*. 2013 Aug;22 Suppl 2:S92-5. doi: 10.1016/j.breast.2013.07.017. PMID: 24074801.
 85. Guarneri V, **Dieci MV**, Barbieri E, Piacentini F, Omarini C, Ficarra G, Bettelli S, Conte PF. Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients. *Ann Oncol*. 2013 Dec;24(12):2990-4. doi: 10.1093/annonc/mdt364. Epub 2013 Sep 7. PMID: 24013581.
 86. Guarneri V, **Dieci MV**, Conte P. Relapsed triple-negative breast cancer: challenges and treatment strategies. *Drugs*. 2013 Aug;73(12):1257-65. doi: 10.1007/s40265-013-0091-6. PMID: 23842749.
 87. Alsafadi S, Even C, Falet C, Goubar A, Commo F, Scott V, Quidville V, Albiges L, **Dieci MV**, Guegan J, Lazar V, Ahomadegbe JC, Delalogue S, André F. Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. *Clin Breast Cancer*. 2013 Oct;13(5):401-8. doi: 10.1016/j.clbc.2013.02.001. Epub 2013 Jul 3. PMID: 23830798.
 88. **Dieci MV**, Arnedos M, Andre F, Soria JC. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. *Cancer Discov*. 2013 Mar;3(3):264-79. doi: 10.1158/2159-8290.CD-12-0362. Epub 2013 Feb 15. PMID: 23418312.
 89. Dogan S, **Dieci MV**, Goubar A, Arnedos M, Delalogue S, Andre F. Landscape and evolution of therapeutic research for breast cancer patients. *Breast Cancer Res Treat*. 2013 Feb;138(1):319-24. doi: 10.1007/s10549-013-2436-y. Epub 2013 Feb 14. PMID: 23408207.
 90. Andre F, **Dieci MV**, Dubsky P, Sotiriou C, Curigliano G, Denkert C, Loi S. Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer. *Clin Cancer*

- Res. 2013 Jan 1;19(1):28-33. doi: 10.1158/1078-0432.CCR-11-2701. Epub 2012 Dec 20. PMID: 23258741.
91. **Dieci MV**, Barbieri E, Piacentini F, Ficarra G, Bettelli S, Dominici M, Conte PF, Guarneri V. Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis. *Ann Oncol*. 2013 Jan;24(1):101-8. doi: 10.1093/annonc/mds248. Epub 2012 Sep 20. PMID: 23002281.
 92. **Dieci MV**, Barbieri E, Bettelli S, Piacentini F, Omarini C, Ficarra G, Balduzzi S, Dominici M, Conte P, Guarneri V. Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. *J Clin Pathol*. 2012 Jun;65(6):503-6. doi: 10.1136/jclinpath-2011-200643. Epub 2012 Mar 3. PMID: 22389512.
 93. Guarneri V, **Dieci MV**, Conte P. Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer. *Expert Opin Pharmacother*. 2012 Feb;13(3):395-406. doi: 10.1517/14656566.2012.651127. Epub 2012 Jan 21. PMID: 22263900.
 94. Maur M, Tomasello C, Frassoldati A, **Dieci MV**, Barbieri E, Conte P. Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. *J Clin Oncol*. 2012 Feb 20;30(6):e76-8. doi: 10.1200/JCO.2011.38.7886. Epub 2011 Dec 27. PMID: 22203769.
 95. Guarneri V, Pecchi A, Piacentini F, Barbieri E, **Dieci MV**, Ficarra G, Tazzioli G, Frassoldati A, Battista R, Canossi B, Mauri C, D'Amico R, Conte P, Torricelli P. Magnetic resonance imaging and ultrasonography in predicting infiltrating residual disease after preoperative chemotherapy in stage II-III breast cancer. *Ann Surg Oncol*. 2011 Aug;18(8):2150-7. doi: 10.1245/s10434-011-1590-x. Epub 2011 Feb 8. PMID: 21301969.
 96. Guarneri V, Barbieri E, **Dieci MV**, Piacentini F, Conte P. Timing for starting second-line therapy in recurrent ovarian cancer. *Expert Rev Anticancer Ther*. 2011 Jan;11(1):49-55. doi: 10.1586/era.10.204. PMID: 21166510.
 97. Guarneri V, Barbieri E, **Dieci MV**, Piacentini F, Conte P. Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer. *Cancer Treat Rev*. 2010 Nov;36 Suppl 3:S62-6. doi: 10.1016/S0305-7372(10)70022-0. PMID: 21129613.
 98. Guarneri V, Giovannelli S, Ficarra G, Bettelli S, Maiorana A, Piacentini F, Barbieri E, **Dieci MV**, D'Amico R, Jovic G, Conte P. Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management. *Oncologist*. 2008 Aug;13(8):838-44. doi: 10.1634/theoncologist.2008-0048. Epub 2008 Jul 23. PMID: 18650259.

3.2 BOOK CHAPTERS

1. Gaia Griguolo, **Maria Vittoria Dieci**, Valentina Guarneri, PierFranco Conte: Breast Cancer: General section. Locoregional and locally advanced disease. «Practical Medical Oncology» Springer Nature, in press.
2. De Placido S, Giuliano M, **Dieci MV**, Conte P : Neoplasie mammarie. In «Manuale di Oncologia Medica», Ed. 1 2018, pp 294-302, Torino : Edizioni Minerva Medica. ISBN 9788877119391.
3. De Laurentiis M, De Placido S, Bianco AR, **Dieci MV**, Guarneri V: Carcinoma della Mammella. In “Core Curriculum. Oncologia Clinica”, Ed. 2 2015, pp 155-184, Milano: Mc-Graw-Hill. ISBN 8838639841
4. Lauria R, Forestieri V, Baretta Z, **Dieci MV** : Tumori ginecologici. In “Core Curriculum. Oncologia Clinica”, Ed. 2 2015, pp 253-269, Milano: Mc-Graw-Hill. ISBN 8838639841
5. Pepe S, Pensabene M, Condello C, Contegiacomo A, Zovato S, **Dieci MV**. Tumori eredo-familiari. In “Core Curriculum. Oncologia Clinica”, Ed. 2, 2015, pp 135-154, Milano: Mc-Graw-Hill. ISBN 8838639841
6. **Dieci MV**, Guarneri V, Giorgi CA, Conte PF: Targeted therapies for HER2-positive breast cancer. In: Russo A, Rosell R, Rolfo C, “Targeted therapies for solid tumors”, 2015, pp 57-72, Springer Science + Business media New York. ISBN: 9781493920464

7. **Dieci MV**, Andre F: Targeting the Fibroblast Growth Factor Receptor Pathway in Human Cancer. In: Giaccone G and Soria JC, "Targeted Therapies in Oncology". Second edition, 2013, p. 157-172, CRC Press, Taylor and Francis group, ISBN: 978-1842145456
8. Conte P, Barbieri E, Guarneri V, Piacentini F, **Dieci MV**: Tumori ginecologici. In: R. Cellerino, G Cetto, A Piga. "Oncologia Clinica Principi e Pratica". 2012, vol. Vol 4, p. 1-83, Rozzano (MI): CEA (Casa Editrice Ambrosiana) Selecta Medica, ISBN/ISSN: 9788808182593

4. ORAL PRESENTATIONS AT NATIONAL AND INTERNATIONAL CONGRESSES

More than 100 oral presentations at national and international congresses.

I hereby authorize the use of my personal data in accordance to the GDPR 679/16 – European regulation on the protection of personal data.

Padova, 30th July 2021

